Antithymocyte globulin (ATG) can be utilized in allogeneic hematopoietic cell transplantation (allo-HCT) conditioning regimens to reduce the risk of GVHD. [1] [2] [3] Although the overall goal of ATG is immunosuppressive in nature, infusion of foreign proteins from the rabbit or equine source can lead to an initial immune response and subsequent infusion reaction symptoms (fever, chills, hypertension and tachycardia) frequently occur. [4] [5] [6] [7] [8] Despite the high incidence of these reactions, strategies for optimal administration of ATG and management of these infusion reaction symptoms are not well documented in the literature. Product labeling recommends premedications (corticosteroid, acetaminophen, antihistamine-1) and suggests a 6-h initial administration time and at least 4 h for administration of subsequent infusions. 6 However, aside from premedication and slowing the infusion rate, recommendations are not made regarding the prevention and management of ATG-related infusion reactions.
Complications of ATG administration can result in numerous deleterious effects. There is the potential need for additional medications as supportive care to ameliorate uncomfortable symptoms, increased nursing time, waste of expired ATG, need for additional ATG to complete the regimen and potential for incomplete administration of the prescribed dose. Furthermore, the cost of nursing time, symptom management including initiation of empiric antibiotics and wasted ATG drug product could be substantial. There is a clear need to investigate optimum administration methods.
In view of these issues, we evaluated two sequential ATG administration protocols at our institution with approval from the local Institutional Review Board. All patients (n = 28) who received rabbit-derived ATG during conditioning for allo-HCT at our institution from 2010 to 2013 were reviewed. In November 2012, rates of ATG infusion reactions prompted a revision of institutional guidelines for ATG administration via consensus of physician, nursing and pharmacy staff. To overcome the high incidence of infusion reactions that had often required interruption of ATG and a significant amount of nursing and provider time, often in the evening hours, the consensus was to set the ATG infusion rate without titration. This was based on our anecdotal experience where those patients who experienced an ATG reaction often tolerated the rest of the ATG when given at a set rate over several hours without further titration.
The institutional historical administration protocol, herein defined as protocol A, administered rabbit-derived ATG 2 mg/kg on days − 4, − 3 and − 2 and titrated over at least 4 h. The revised administration protocol, herein defined as protocol B, extended the administration of ATG as follows: 1 mg/kg days − 5 and − 2 and 2 mg/kg days − 4 and − 3 at a fixed rate over 20 h. All patients were premedicated with methylprednisolone 60 mg i.v. and diphenhydramine 50 mg p.o. on both protocols, but patients on protocol B additionally received diphenhydramine 25 mg p.o. three times a day and famotidine 20 mg p.o. twice a day during ATG administration. All patients received the following prophylaxis: ursodiol for sinusoidal obstructive syndrome, tacrolimus and MTX for GVHD, as well as levofloxacin, acyclovir and either fluconazole or voriconazole for infections. No patient received a test dose of ATG.
Administration and clinical outcomes were retrospectively compared between patients treated on each administration protocol (n = 14 each). Administration outcomes included the number of infusion interruptions, administration of additional corticosteroids, amount of additional ATG needed and the number of patients unable to complete the regimen. Clinical outcomes included data on GVHD and infections including the number and type of microbiologically defined infections and number of patients with escalation to empiric antibacterial and/or treatment dose antifungal.
With regard to demographics, patients treated on protocol A had a median age of 49 years (range 24-64 years), 57% male, 79% Caucasian, 71% 10/10 HLA match and 93% received fludarabine +BU, whereas 7% received BU+CY conditioning regimen. Patients on protocol B had a median age of 52 years (range 32-67 years), 64% male, 93% Caucasian, 93% 10/10 HLA match and 79% received fludarabine+BU, whereas 14% received BU+CY and 7% fludarabine+CY conditioning regimen. Over the course of ATG administration, the infusion was interrupted 12 times for 14 patients treated on protocol A and 7 times for 14 patients on protocol B. When each dose of ATG was treated independently, the number of times the infusion was interrupted over the course of ATG administration was not significantly different between protocols (28.6% vs 12.5%, P = 0.0696; Fisher's exact). The number of times additional steroids were administered for ATG infusion reaction management was significantly more frequent in protocol A vs B (P = 0.0001; Fisher's exact) ( Table 1) . No clear association between protocols was found with respect to the number of patients experiencing fever, rigors, tachycardia and/or alterations in blood pressure on each ATG day (data not shown). Although the percent of patients experiencing fever, rigors or tachycardia appeared to be lower for protocol B on the first 2 days of ATG, this was not consistent for alterations in blood pressure or for the third day. For each ATG infusion day the mean heart rates did not appear to be different between groups.
In both groups, 3/14 (21%) had the ATG infusion interrupted due to infusion reaction symptoms and were not able to receive the full dose on the prescribed day. For patients on protocol A, the amount administered on an additional day to complete the regimen ranged 11-33% of the total ATG dose vs 2.5-11% for patients on protocol B. Given dose rounding policies at many institutions, a difference between ordered and administered of o5-10% may be considered clinically irrelevant. Notably, two of the three patients in protocol B had the make-up dose added to the last scheduled day of ATG; this allowed for less additional steroid premedication and a reduction in nursing administration time for make-up doses for patients treated on protocol B.
Importantly, all patients treated on both protocols successfully received the full amount of ATG prescribed.
As for clinical outcomes, infectious complications in the first 30 days post transplant were similar for protocols A and B ( Table 2 ). The numbers of patients with an escalation of empiric antibiotics, escalation to empiric treatment dose antifungal, admission to the intensive care unit and/or a microbiologically defined infection were similar between the groups. With regard to GVHD, 11/14 (79%) of patients from protocol A and 14/14 (100%) of patients from protocol B had documentation of acute GVHD. The median time to onset was similar (20 (range 16-174) vs 23.5 (9-54) days for protocol A vs B). For those treated on protocol A, 45% had grade I-II and 55% grade III-IV, whereas for patients on protocol B, 64% had grade I-II and 36% grade III-IV. More patients on protocol A required second-line treatment for steroidrefractory GVHD (72% vs 21%). In addition, more patients from protocol A had documentation of chronic GVHD (36% vs 14%). Notably, the difference in median time to follow-up between the two sequential groups must be taken into consideration (366 (25-849) vs 150 (48-421) days, respectively) when evaluating these clinical outcomes.
Infusion of ATG during conditioning for allo-HCT is associated with several practical issues for patients, nursing staff and clinicians. Infusion reactions require prompt assessment often interrupting patient-care activities throughout the day and night. Time encumbered by nursing and medical staff to assess and manage these infusion reactions is not minimal. The set infusion rate for protocol B requires substantially less nursing time than the titrated infusion from protocol A. Management of ATG infusion reactions can involve addition of numerous medication interventions such as meperidine for rigors, ibuprofen for fevers and empiric antimicrobials for fevers. If a patient is already neutropenic, the addition of antibiotics may not be considered irreversible until resolution of neutropenia post transplant. The clinical and financial implications are notable. Management of infusion reactions may require slowing the infusion rate or interrupting the infusion until symptoms resolve, and owing to the short expiration of ATG i.v. bag (24 h) this may lead to wasting of drug product. The cost of wasting partial ATG infusion bags and cost of additional ATG to make up for the missed dose could be substantial (2013 average wholesale price for 25 mg vial~$750 and the average sales price~$570). Therefore, using the average sales price an estimated cost for entire ATG course in a 70-kg patient would be $9690. Using the average sales price to calculate the actual cost of waste and make-up doses from protocol A would have been $12 540 as compared with $9840 for the cost of waste and make-up doses from protocol B. However, it must also be taken into account that two of three patients on protocol B were able to have this make-up dose added to the last scheduled day of ATG, thus saving nursing administration and monitoring time. Furthermore, many institutions have dose rounding protocols of 5-10%; therefore, make-up doses of less than this amount may not be required.
Administration of ATG during conditioning for allo-HCT is an area for continued improvement. In this pilot study, slowing the infusion rate over 4 days with the addition of histamine blockade around the clock improved the number of infusion reactions and significantly reduced the need for additional steroids as well as the amount of make-up doses of ATG. Given the reduced incidence of interruptions of ATG infusion, administration of additional steroid doses and satisfaction from nursing and providers, protocol B is now the standard protocol for our institution. For institutions that perform outpatient transplants, this administration method may be limited; however, addition of around the clock antihistamine blockade and a fixed infusion rate can still be considered in those situations. Optimal methods to reduce infusion reactions should continue to be explored.
